Latest Breaking News On - Ton logtenberg - Page 7 : comparemela.com

Zacks: Brokerages Expect Merus (NASDAQ:MRUS) to Post -$0 64 EPS

Equities research analysts expect that Merus (NASDAQ:MRUS – Get Rating) will post earnings of ($0.64) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Merus’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.69). Merus posted earnings per share of ($0.28) in the same quarter […]

Zurcher kantonalbank zurich cantonalbankDekabank deutsche girozentraleNeedham companyJpmorgan chase coMerus company profile get ratingZacks investment researchMacquarie group ltdRoyal bankGet ratingInvestment researchKantonalbank zurich cantonalbankCompany profileTon logtenbergHennie hoogenboomNasdaq mrus

Brokerages Anticipate Merus (NASDAQ:MRUS) Will Announce Earnings of -$0 58 Per Share

Brokerages Anticipate Merus (NASDAQ:MRUS) Will Announce Earnings of -$0 58 Per Share
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Thomson reuterZacks investment researchMacquarie group ltdCitigroup incJump financialRoyal bankMerus company profileZacks investmentRoth capitalBvf partnersTon logtenbergHennie hoogenboom

SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer

SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesGray barlowFrancesco de rubertisJacob gunterbergKiadis pharmaSynox therapeutics limitedEmergent biosolutions incSynox therapeuticsTenosynovial giant cell tumoursChief executive officerTon logtenbergChief scientific officerChief business officerSynox therapeutics boardNick la thangueCelleron therapeutics